All issues
Volume 23 (2008)
- Issue 6 Pages 610-
- Issue 5 Pages 518-
- Issue 4 Pages 448-
- Issue 2 Pages 112-
- Issue 1 Pages 24-
Volume 23, Issue 4
Displaying 1-5 of 5 articles from this issue
- |<
- <
- 1
- >
- >|
Feature articles “Development of DDS for respiratory diseases” Editor : Shigeru Kohno
-
Katsunori Yanagihara, Shigeru Kohno2008 Volume 23 Issue 4 Pages 448-453
Published: 2008
Released on J-STAGE: October 07, 2008
JOURNAL FREE ACCESSAccording to the Japanese Ministry of Health, Labour and Welfare (MHLW), pneumonia is the fourth leading cause of death in Japan. Respiratory tract infection such as pneumonia is important for the elderly patients. Thus, the development of DDS with the aim of reducing the frequency of dosing and improving compliance is also suggestive of a new trend for DDS in the field of treating Respiratory tract infection.
Azithromycin-SR will be released as the choice for community-acquired pneumonia in near future. Liposomal amphotericin B for empirical therapy in patients with deep seated mycosis is useful for clinicians. Inhaled amikacin and the new pulmonary drug delivery system have been expected as the new treatment for the patients infected with resistant bacteria.View full abstractDownload PDF (453K) -
Hidefumi Mukai, Shigeru Kawakami, Mitsuru Hashida2008 Volume 23 Issue 4 Pages 454-459
Published: 2008
Released on J-STAGE: October 07, 2008
JOURNAL FREE ACCESSThe lung is one of the most important target organs for gene therapy because there are many genetic and acquired lung diseases, for which there are no effective treatment protocols. In particular, clinical trials of gene therapy for cystic fibrosis, α-1-antitrypsin deficiency and lung cancer are being carried out. This reason is that the mechanism of these diseases is comparatively clear and therapeutic effect is hoped to be obtained by single gene administration. The lung is non-invasively accessible through the vasculature and airways, and therefore, the realization of gene therapy will be achieved by the development of more suitable gene delivery system for individual lung diseases in the near future. In this article, we collect the information of therapeutic gene and target cells for lung diseases and structure of lung from the point of view of gene delivery. Additively, current status of gene delivery technology to the lung is reviewed.View full abstractDownload PDF (301K) -
Takayoshi Yoshikawa, Kohsaku Kawakami, Eri Kanaoka2008 Volume 23 Issue 4 Pages 460-466
Published: 2008
Released on J-STAGE: October 07, 2008
JOURNAL FREE ACCESSInhalation therapy, which is regarded as highly effective administration methodology for various pulmonary diseases, can be more fascinating by employing liposomal technology. Clinical studies on liposomal inhalable formulations are already ongoing, and thus they may become available in near future. In this review, recent results on the formulation development studies and current status on their clinical applications are summarized.View full abstractDownload PDF (354K) -
Yuichi Tozuka, Hirofumi Takeuchi2008 Volume 23 Issue 4 Pages 467-473
Published: 2008
Released on J-STAGE: October 07, 2008
JOURNAL FREE ACCESSPulmonary drug administration has many advantages over other delivery routes in both local and systemic drug delivery, since the lungs have a large surface area, thin absorption barrier and low enzymatic metabolic activity. We have reported several methods to design and prepare the submicron-sized particles suitable for nebulization or dry powder inhalation. Elcatonin loaded surface-modified DL-lactide/glycolide copolymer (PLGA) nanospheres coated with chitosan (CS) were prepared by the emulsion solvent diffusion method for pulmonary delivery of peptide. The resultant CS-modified PLGA nanospheres were confirmed to improve the pulmonary delivery of peptide with a nebulization system. With respect to the dry powder inhalation, nanoparticles of drugs could be obtained by a novel supercritical carbon dioxide method with a combination of supercritical antisolvent precipitation and rapid expansion from supercritical to aqueous solution. The resulting particles showed superior inhalation properties in an in vitro inhalation test using the cascade impactor. Nanotechnology focusing at particle design to control the particle size and surface properties may be a promising tool for developing effective pulmonary delivery systems.View full abstractDownload PDF (444K) -
Hiroyuki Inagawa, Chie Kohchi, Gen-ichiro Soma, Makoto Matsumoto, Shuj ...2008 Volume 23 Issue 4 Pages 474-480
Published: 2008
Released on J-STAGE: October 07, 2008
JOURNAL FREE ACCESSAs Asia has been suffered greatly from various infectious diseases, such as tuberculosis, AIDS and malaria, it is very important to establish the efficient drug delivery system(DDS) against these diseases. Tuberculosis is caused by Mycobacterium tuberculosis, AIDS is by human immunodeficiency virus (HIV) and malaria is by plasmodium. In this review article, DDS for the treatment of tuberculosis will be presented. Tubercle bacilli are phagocytosed by macrophages but are not digested. To overcome this problem, we have started with two strategies, 1) develop a dosage form/formulation of DDS making pathogens more easily to be phagocytosed by macrophages, 2) activate the phagocytotic capacity of pathogen -infected macrophages.View full abstractDownload PDF (657K)
- |<
- <
- 1
- >
- >|